L. Ryom

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of changes in body mass index on the risk of cardiovascular disease and diabetes mellitus in HIV-positive individuals: results from the D: A: D study\.

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2020, Journal of acquired immune deficiency syndromes.

Body Mass Index and the Risk of Serious Non-AIDS Events and All-Cause Mortality in Treated HIV-Positive Individuals: D A D Cohort Analysis

A. Mocroft, R. Weber, C. Sabin, 2018, Journal of acquired immune deficiency syndromes.

Risk for Non–AIDS-Defining and AIDS-Defining Cancer of Early Versus Delayed Initiation of Antiretroviral Therapy

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2021, Annals of Internal Medicine.

HIV Therapies and the Kidney: Some Good, Some Not So Good?

A. Mocroft, J. Lundgren, L. Ryom, 2012, Current HIV/AIDS Reports.

Cumulative and current exposure to potentially nephrotoxic antiretrovirals and development of chronic kidney disease in HIV-positive individuals with a normal baseline estimated glomerular filtration rate: a prospective international cohort study.

A. Mocroft, O. Kirk, P. Reiss, 2016, The lancet. HIV.

Associations between serum albumin and serious non-AIDS events among people living with HIV

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2018, AIDS.

Prevalence of impaired renal function in virologically suppressed people living with HIV compared with controls: the Copenhagen Comorbidity in HIV Infection (COCOMO) study*

A. Mocroft, J. Lundgren, P. Oturai, 2019, HIV medicine.

Prevalence of impaired renal function in virologically suppressed people living with HIV compared with controls: the COCOMO study

A. Mocroft, J. Lundgren, P. Oturai, 2019 .

Antiretroviral Drugs and Risk of Chronic Alanine Aminotransferase Elevation in Human Immunodeficiency Virus (HIV)-Monoinfected Persons: The Data Collection on Adverse Events of Anti-HIV Drugs Study

O. Kirk, A. d’Arminio Monforte, R. Weber, 2016, Open forum infectious diseases.

Contemporary protease inhibitors and cardiovascular risk

A. Mocroft, J. Lundgren, L. Ryom, 2018, Current opinion in infectious diseases.

Oral abstracts of the 21st International AIDS Conference 18–22 July 2016, Durban, South Africa

Michael I. Jordan, Donald A. Jackson, J. G. Ndirangu, 2016, Journal of the International AIDS Society.

Short‐term weight gain after antiretroviral therapy initiation and subsequent risk of cardiovascular disease and diabetes: the D:A:D study

A. Mocroft, A. d’Arminio Monforte, J. Lundgren, 2016, HIV medicine.

Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

A. Mocroft, O. Kirk, M. Johnson, 2015, PLoS medicine.

Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium.

A. Mocroft, A. d’Arminio Monforte, H. Günthard, 2022, The lancet. HIV.

Association Between ALT Level and the Rate of Cardio/Cerebrovascular Events in HIV-Positive Individuals: The D:A:D Study

O. Kirk, C. Sabin, A. Phillips, 2013, Journal of acquired immune deficiency syndromes.

Assessing HIV-positive Persons’ Readiness to Start and Maintain ART

W. Langewitz, M. Battegay, D. Nicca, 2013 .

Major revision version 11.0 of the European AIDS Clinical Society Guidelines 2021

O. Kirk, A. Winston, C. Marzolini, 2022, HIV medicine.

Contemporary antiretrovirals and body-mass index: a prospective study of the RESPOND cohort consortium.

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2021, The lancet. HIV.

Incidence and risk factors for suicide, death due to substance use, and violent/accidental death in people with HIV

A. Mocroft, P. Reiss, J. Reekie, 2022, AIDS.

Ritonavir-Boosted Protease Inhibitors Do Not Significantly Affect the Performance of Creatinine-Based Estimates of GFR

A. Levey, A. Mocroft, L. Inker, 2020, Kidney international reports.

Tenofovir disoproxil fumarate withdrawal and cardiovascular risk – Authors' reply

A. Mocroft, L. Ryom, L. Peters, 2023, The Lancet HIV.

Antiretroviral therapy, immune suppression and renal impairment in HIV-positive persons

A. Mocroft, J. Lundgren, L. Ryom, 2014, Current opinion in HIV and AIDS.

The benefits and risks of PrEP and kidney function.

A. Mocroft, L. Ryom, 2016, The lancet. HIV.

Cardiovascular disease and use of contemporary protease inhibitors: the D:A:D international prospective multicohort study.

Peter Reiss, Ole Kirk, Eric Fontas, 2018, The lancet. HIV.

Highlights of the 2017 European AIDS Clinical Society (EACS) Guidelines for the treatment of adult HIV‐positive persons version 9.0

S. McCormack, A. Mocroft, O. Kirk, 2018, HIV medicine.

Trends in underlying causes of death in people with HIV from 1999 to 2011 (D:A:D): a multicohort collaboration

O. Kirk, R. Weber, C. Sabin, 2014, The Lancet.

Predictors of eGFR progression, stabilisation or improvement after chronic renal impairment in HIV-positive individuals.

A. Mocroft, O. Kirk, C. Sabin, 2017, AIDS.

Essentials from the 2015 European AIDS Clinical Society (EACS) guidelines for the treatment of adult HIV‐positive persons

J. Lundgren, M. Battegay, H. Furrer, 2016, HIV medicine.

Predictors of Ischemic and Hemorrhagic Strokes Among People Living With HIV: The D:A:D International Prospective Multicohort Study☆

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2019, EClinicalMedicine.

Increased risk of cardiovascular disease (CVD) with age in HIV‐positive men: a comparison of the D:A:D CVD risk equation and general population CVD risk equations

O. Kirk, A. d’Arminio Monforte, J. Lundgren, 2014, HIV medicine.

Aging and the evolution of comorbidities among HIV-positive individuals in a European cohort

A. Mocroft, B. Clotet, J. Lundgren, 2018, AIDS.

Association between exposure to antiretroviral drugs and the incidence of hypertension in HIV‐positive persons: the Data Collection on Adverse Events of Anti‐HIV Drugs (D:A:D) study

O. Kirk, A. d’Arminio Monforte, C. Sabin, 2018, HIV medicine.

International Congress of Drug Therapy in HIV Infection 23-26 October 2016, Glasgow, UK

Raúl Tabarés Gutiérrez, Samit R. Joshi, H. Jessen, 2016, Journal of the International AIDS Society.

Cancer Risk and Use of Protease Inhibitor or Nonnucleoside Reverse Transcriptase Inhibitor–Based Combination Antiretroviral Therapy: The D:A:D Study

C. Sabin, H. Furrer, P. Reiss, 2015, Journal of acquired immune deficiency syndromes.

Cardiovascular disease (CVD) and chronic kidney disease (CKD) event rates in HIV-positive persons at high predicted CVD and CKD risk: A prospective analysis of the D:A:D observational study

A. Mocroft, R. Weber, C. Sabin, 2017, PLoS medicine.

Cancer risk and use of PI or NNRTI-based combination antiretroviral therapy (cART): The D:A:D Study

C. Sabin, A. Phillips, P. Reiss, 2013 .

Prevalence and outcomes of pregnancies in women living with HIV over a 20-year period: The EuroSIDA study, 1996 to 2015.

A. Mocroft, M. Battegay, D. Raben, 2021, AIDS.

Is nelfinavir exposure associated with cancer incidence in HIV-positive individuals?

O. Kirk, C. Sabin, A. Phillips, 2016, AIDS.

Differences in Virological and Immunological Risk Factors for Non-Hodgkin and Hodgkin Lymphoma

A. Mocroft, C. Sabin, M. Battegay, 2017, Journal of the National Cancer Institute.

International Congress of Drug Therapy in HIV Infection 2‐6 November 2014, Glasgow, UK

Samit R. Joshi, Charlene A Flash, Thomas Lengauer, 2014 .

Uptake and effectiveness of two-drug compared to three-drug antiretroviral Regimens among HIV-positive Individuals in Europe.

A. Mocroft, J. Lundgren, V. Vullo, 2019, AIDS.

2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0

O. Kirk, A. Wensing, A. Winston, 2020, HIV medicine.

Clinical management of ageing people living with HIV in Europe: the view of the care providers

J. Rockstroh, C. Spinner, M. Boffito, 2020, Infection.

Association between antiretroviral exposure and renal impairment among HIV-positive persons with normal baseline renal function: the D:A:D study.

Peter Reiss, Ole Kirk, Lene Ryom, 2013, The Journal of infectious diseases.

Are we successfully managing cardiovascular disease in people living with HIV?

J. Lundgren, C. Hatleberg, L. Ryom, 2017, Current opinion in HIV and AIDS.

Novel hepatitis B virus reverse transcriptase mutations in patients with sustained viremia despite long-term tenofovir treatment.

J. Bukh, A. Winckelmann, Andreas Lundh, 2022, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Recent abacavir use and incident cardiovascular disease in contemporary-treated people with HIV

A. Mocroft, A. d’Arminio Monforte, H. Günthard, 2022, AIDS.

Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium

A. Mocroft, J. Gallant, F. Wit, 2022, HIV medicine.

A comparison of estimated glomerular filtration rates using Cockcroft−Gault and the Chronic Kidney Disease Epidemiology Collaboration estimating equations in HIV infection

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2013, HIV Medicine.

A clinically useful risk-score for chronic kidney disease in HIV infection

A. Mocroft, O. Kirk, M. Johnson, 2014, Journal of the International AIDS Society.

Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study.

A. Mocroft, O. Kirk, C. Sabin, 2016, The Journal of infectious diseases.

Kidney disease in antiretroviral‐naïve HIV‐positive adults with high CD4 counts: prevalence and predictors of kidney disease at enrolment in the INSIGHT Strategic Timing of AntiRetroviral Treatment (START) trial

A. Mocroft, H. Furrer, J. Neuhaus, 2015, HIV medicine.

Cardiovascular risks associated with protease inhibitors for the treatment of HIV

C. Sabin, C. Hatleberg, L. Ryom, 2021, Expert opinion on drug safety.

Antiretroviral drug-related liver mortality among HIV-positive persons in the absence of hepatitis B or C virus coinfection: the data collection on adverse events of anti-HIV drugs study.

R. Weber, C. Sabin, A. Phillips, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

An updated prediction model of the global risk of cardiovascular disease in HIV-positive persons: The Data-collection on Adverse Effects of Anti-HIV Drugs (D:A:D) study

O. Kirk, R. Weber, C. Sabin, 2016, European journal of preventive cardiology.

Cost‐effectiveness of statins for primary prevention of atherosclerotic cardiovascular disease among people living with HIV in the United States

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2021, Journal of the International AIDS Society.

Chronic Kidney Disease and Antiretroviral Therapy in HIV-Positive Individuals: Recent Developments

A. Mocroft, C. Wyatt, Melinda M. Nugent, 2016, Current HIV/AIDS Reports.

Lack of association between use of efavirenz and death from suicide: evidence from the D:A:D study

A. Mocroft, A. d’Arminio Monforte, R. Weber, 2014, Journal of the International AIDS Society.

Use of Contemporary Protease Inhibitors and Risk of Incident Chronic Kidney Disease in Persons With Human Immunodeficiency Virus: the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) Study

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2019, The Journal of Infectious Diseases.

Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study

A. Mocroft, O. Kirk, C. Sabin, 2014, BMC Nephrology.

Use of contemporary protease inhibitors and risk of incident chronic kidney disease in HIV-positive persons; the D:A:D Study.

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2019, The Journal of infectious diseases.

Prevalence and characteristics of chronic kidney disease among Danish adults with cystic fibrosis.

L. Ryom, D. Faurholt-Jepsen, T. Katzenstein, 2018, Journal of cystic fibrosis : official journal of the European Cystic Fibrosis Society.

Serious clinical events in HIV-positive persons with chronic kidney disease (CKD).

A. Mocroft, O. Kirk, R. Weber, 2019, AIDS.

Predictors of estimated glomerular filtration rate progression, stabilization or improvement after chronic renal impairment in HIV-positive individuals.

A. Mocroft, O. Kirk, C. Sabin, 2017, AIDS.

Clinical outcomes of two-drug regimens vs. three-drug regimens in antiretroviral treatment-experienced people living with HIV.

R. Haubrich, C. Leen, A. Mocroft, 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Association between dideoxynucleoside analogues (d-Drugs) and end-stage liver disease (ESLD)

O. Kirk, C. Sabin, A. Phillips, 2014 .

Potential drug–drug interactions between antiretroviral drugs and comedications, including dietary supplements, among people living with HIV: A clinical survey

O. Kirk, T. Benfield, A. Hansen, 2022, HIV medicine.

Trends in Cancer Incidence in Different Antiretroviral Treatment-Eras amongst People with HIV

A. Mocroft, A. d’Arminio Monforte, C. Sabin, 2023, Cancers.

Contribution of Genetic Background and Data Collection on Adverse Events of Anti–human Immunodeficiency Virus (HIV) Drugs (D:A:D) Clinical Risk Score to Chronic Kidney Disease in Swiss HIV-infected Persons With Normal Baseline Estimated Glomerular Filtration Rate

J. Fellay, H. Furrer, E. Bernasconi, 2019, Clinical Infectious Diseases.

Contribution of genetic background and clinical D:A:D risk score to chronic kidney disease in Swiss HIV-positive persons with normal baseline estimated glomerular filtration rate.

J. Fellay, H. Furrer, E. Bernasconi, 2019, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Antiretroviral Drugs Associated with Chronic ALT Elevations in Persons without HCV and HBV Infection

R. Weber, C. Sabin, A. Phillips, 2015 .

Gender differences in the use of cardiovascular interventions in HIV‐positive persons; the D:A:D Study

A. Mocroft, A. d’Arminio Monforte, C. Sabin, 2018, Journal of the International AIDS Society.

Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study

A. Mocroft, O. Kirk, C. Sabin, 2014, BMC Nephrology.

Renal Impairment and Cardiovascular Disease in HIV-Positive Individuals: The D:A:D Study.

A. Mocroft, O. Kirk, C. Sabin, 2016, The Journal of infectious diseases.

Deteriorating renal function and clinical outcomes in HIV-positive persons

A. Mocroft, O. Kirk, J. Gatell, 2014, AIDS.

Rapid Progression of Kidney Dysfunction in Swiss People Living with HIV: Contribution of Polygenic Risk Score and D:A:D Clinical Risk Score.

E. Bernasconi, B. Ledergerber, P. Schmid, 2020, The Journal of infectious diseases.

Association of a Polygenic Risk Score With Osteoporosis in People Living With HIV: The Swiss HIV Cohort Study

J. Fellay, H. Günthard, E. Bernasconi, 2023, The Journal of infectious diseases.

Impact of short-term change in body mass index (BMI) after antiretroviral therapy (ART) initiation on subsequent risk of cardiovascular disease (CVD) and diabetes in HIV-positive individuals: the D:A:D study

A. Mocroft, R. Weber, C. Sabin, 2014 .

Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study

A. Mocroft, Esprit study groups, L. Ryom, 2015, PLoS medicine.

Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consort

A. Mocroft, C. Mussini, K. Petoumenos, 2024, The lancet. HIV.